NCT05338307View on ClinicalTrials.gov

Preliminary Investigation of β-hydroxybutyrate Supplementation in Colorectal Cancer Prevention

NAActive, not recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 13, 2022

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Colorectal Cancer
Interventions
DIETARY_SUPPLEMENT

R-1,3-Butanediol

Study participants will be taking 35mL of HVMN Ketone-IQ by mouth three times daily, with each dose containing 10 grams of R-1,3-Butanediol.

Trial Locations (1)

19104

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

All Listed Sponsors
lead

Abramson Cancer Center at Penn Medicine

OTHER